NASDAQ:FLKS - Flex Pharma Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
$13.69
0.00 (0.00 %)
(As of 07/25/2019)
Today's Range
$133.35
Now: $13.69
$134.34
50-Day Range
$0.57
MA: $6.86
$14.51
52-Week Range
$0.26
Now: $13.69
$1.49
Volume40,309 shs
Average Volume2.03 million shs
Market Capitalization$247.38 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65
Flex Pharma, Inc, a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLKS
CUSIPN/A
Phone617-874-1821

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$840,000.00
Book Value$0.51 per share

Profitability

Net Income$-21,920,000.00
Net Margins-1,208.42%

Miscellaneous

Employees4
Market Cap$247.38 million
Next Earnings DateN/A
OptionableOptionable

Receive FLKS News and Ratings via Email

Sign-up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter.


Flex Pharma (NASDAQ:FLKS) Frequently Asked Questions

What is Flex Pharma's stock symbol?

Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."

How were Flex Pharma's earnings last quarter?

Flex Pharma Inc (NASDAQ:FLKS) announced its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported ($0.12) earnings per share for the quarter. The biotechnology company had revenue of $0.11 million for the quarter. Flex Pharma had a negative net margin of 1,208.42% and a negative return on equity of 98.04%. View Flex Pharma's Earnings History.

Has Flex Pharma been receiving favorable news coverage?

Media coverage about FLKS stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Flex Pharma earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Flex Pharma.

Who are some of Flex Pharma's key competitors?

What other stocks do shareholders of Flex Pharma own?

Who are Flex Pharma's key executives?

Flex Pharma's management team includes the folowing people:
  • Dr. William K. McVicar, Pres, CEO & Director (Age 61)
  • Dr. Roderick MacKinnon, Co-Founder & Co-Chair of Scientific Advisory Board (Age 63)
  • Mr. John McCabe, CFO, Treasurer & Sec. (Age 49)
  • Dr. Thomas C. Wessel, Outside Advisor (Age 63)
  • Dr. Bruce Bean, Co-Founder, Co-Chair of Scientific Advisory Board & Board Observer

When did Flex Pharma IPO?

(FLKS) raised $60 million in an IPO on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

Who are Flex Pharma's major shareholders?

Flex Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (7.70%) and Ahrens Investment Partners LLC (0.78%). Company insiders that own Flex Pharma stock include Boston Foundation, Inc and Christoph H Westphal. View Institutional Ownership Trends for Flex Pharma.

Which institutional investors are selling Flex Pharma stock?

FLKS stock was sold by a variety of institutional investors in the last quarter, including Ahrens Investment Partners LLC. Company insiders that have sold Flex Pharma company stock in the last year include Boston Foundation, Inc and Christoph H Westphal. View Insider Buying and Selling for Flex Pharma.

Which institutional investors are buying Flex Pharma stock?

FLKS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Flex Pharma.

What is Flex Pharma's stock price today?

One share of FLKS stock can currently be purchased for approximately $13.69.

How big of a company is Flex Pharma?

Flex Pharma has a market capitalization of $247.38 million and generates $840,000.00 in revenue each year. Flex Pharma employs 4 workers across the globe.View Additional Information About Flex Pharma.

What is Flex Pharma's official website?

The official website for Flex Pharma is http://www.flex-pharma.com/.

How can I contact Flex Pharma?

Flex Pharma's mailing address is 31 St. James Avenue 6thFloor, Boston MA, 02116. The biotechnology company can be reached via phone at 617-874-1821 or via email at [email protected]


MarketBeat Community Rating for Flex Pharma (NASDAQ FLKS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  334 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  573
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe FLKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel